All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-06-24T08:45:00.000Z

Germline predisposition mutations and recurrent somatic mutations in Korean patients with ALL

Jun 24, 2021
Share:

Bookmark this article

The two most common malignancies in children are B-cell precursor and T-cell precursor acute lymphoblastic leukemia (B-ALL, T-ALL). Although genetic variations can be used to classify ALL, these are numerous and heterogenous. The 2016 revision to the World Health Organization (WHO) classification of ALL, added new provisional entities: BCR-ABL1-like (or Ph-like) ALL, iAMP21 (intrachromosomal amplification of chromosome 21), and early T-cell precursor ALL (ETP-ALL).1 In addition to somatic mutations, the WHO classification also included genes that are associated with predisposition to myeloid neoplasms including CEBPA, DDX41, RUNX1, ANKRD26, ETV6, and GATA2. There are also several syndromes that increase susceptibility to ALL including Li Fraumeni (TP53), and Wiskott Aldrich syndrome (WAS). Some genes (PAX5, ETV6, TP53, and IKZF1) associated with ALL are found to have both germline and somatic mutations, thus increasing the susceptibility to ALL. The ALL Hub has previously published an article describing the different genes impacted by germline mutations.

In a recently published study by Shin et al., the association of genetic alterations and predisposition to ALL in both pediatric and adult patients was investigated.1 The key findings are summarized below.

Methods

The study investigated genetic alterations in Korean patients with ALL using targeted gene panel sequencing.

Paired initial diagnosis and complete remission (CR) bone marrow samples from patients with ALL were selected.

Bone marrow slides of when the patients were in CR were used to detect germline mutations. Nearly a third of the patients had received allogeneic stem cell transplantation (allo-SCT), and in these patients, CR status bone marrow slides before transplantation were used to detect germline mutations. Slides with no apparent residual leukemic cells were used as control samples.

A gene panel consisting of 81 genes, known to be associated with 23 predisposition syndromes, was investigated. In addition to sequence variants, gene-level copy number variations (CNVs) were investigated.

Results

Baseline characteristics

In total, 65 pediatric (<20 years) and 28 adult patients with ALL were included. Patient characteristics are summarized in Table 1. The most common type of B-ALL in adults was BCR-ABL1, whereas in children was B-ALL not otherwise specified (NOS) and B-ALL with hyperdiploidy.

Table 1. Patient characteristics*

Characteristic

Children
(n = 65)

Adults
(n = 28)

Sex, n

              Male

35

10

              Female

30

18

Diagnosis, n

              B-ALL, NOS

25

8

              B-ALL with t(9;22)(q34.1;q11.2); BCR-ABL1

2

11

              B-ALL with t(v;11q23.3); KMT2A rearranged

4

1

              B-ALL with t(12;21)(p13.2; q22.1); ETV6-RUNX1

9

0

              B-ALL with hyperdiploidy

16

1

              B-ALL with t(1;19)(q23; p13.3); TCF3-PBX1

2

2

              T-ALL

5

5

              Early T-cell precursor acute leukemia

2

0

B-ALL cytogenic risk group, n

              Good

26

2

              Intermediate

26

9

              High

6

12

B-ALL, B-cell acute lymphoblastic leukemia; NOS, not otherwise specified; T-ALL, T-cell acute lymphoblastic leukemia.
*Data from Shin et al.1

Germline sequence variants

Only one pathogenic TP53 variant (Accession: NM_000546.5) was identified in an adult patient with B-ALL NOS. A known CNV, CASP10 (Accession: NM_032977.3), was identified in one pediatric patient with B-ALL NOS.

Five heterozygous autosomal recessive (AR) primary immunodeficiency disorder (PID)-associated gene variants were identified in five other patients (as shown in Table 2).

Table 2. Germline sequence variants*

Patient ID

Age/Sex

Gene

% variant

Syndrome

ALL0009

51/F

TP53

40.3

Li-Fraumeni syndrome

ALL0067

18/M

CASP10

Autoimmune lymphoproliferative syndrome, Type II

ALL0077

10/M

TYK2

40.2

Immunodeficiency 35, AR

ALL0053

2/M

IL12RB1

50.7

Immunodeficiency 30, AR

ALL0060

40/M

LPIN2

44.0

Majeed syndrome, AR

ALL0071

2/F

CTC1

47.0

Dyskeratosis congenital, AR

ALL0021

2/M

LIG4

42.6

LIG4 syndrome, AR

AR, autosomal recessive; F, female; M, male.
*Data from Shin et al.1

Somatic sequence variants

A total of 197 somatic sequence variants and 223 somatic CNV were identified. The most common somatic sequence variants and CNVs in B-ALL and T-ALL patients are shown in Table 3. All NRAS and KRAS variants were previously reported variants. The majority of the FLT3 variants were known variants in hematological malignancies, and about 50% of the PAX5 variants were also recurrent variants.

Table 3. Somatic sequence variants*

Sequence variant

%

Somatic sequence variant in T-ALL

              NOTCH1

50

              FBXW7

25

              IL7R

25

              NRAS

25

              DNMT3A

17

              PHF6

17

              GATA3

17

Somatic sequence variant in B-ALL

              NRAS

17

              FLT3

14

              KRAS

9

              SETD2

7

              PAX5

6

              CREBBP

6

CNV in T-ALL

              CDKN2A/B

50

              CRLF2

17

              GATA3

8

              CSF2RA

8

              BCOR

8

CNV in B-ALL

              CDKN2A/B

31

              IKZF1

16

              ETV6

12

              ERG

12

              RB1

11

B-ALL, B-cell acute lymphoblastic leukemia; CNV, copy number variations; T-ALL, T-cell acute lymphoblastic leukemia.
*Data from Shin et al.1

IKZF1 alterations were present in 15 B-ALL patients:

  • Seven patients had B-ALL with BCR-ABL1 and all had an IKZF1 deletion.
  • Out of seven B-ALL patients with NOS, six had an IKZF1 deletion and one had a IKZF1 frameshift mutation.
  • Only one patient with T-ALL had an IKZF1 alteration (missense mutation).
  • Three B-ALL patients with BCR-ABL1 and two with B-ALL NOS with IKZF1 deletions also had deletion of PAX5.
  • The frequency of IKZF1 deletion was higher in the adult high-risk cytogenic group (6/12, 50%) compared with the overall B-ALL group (13/81, 16%). This may be due to most adult cases (11/12) being ALL with BCR-ABL1.
  • The study also found high concordance (83.7%) between fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS) for CDKN2A/B.
  • Statistically significant differences were seen in the overall survival (OS) and relapse-free survival (RFS) (p < 0.5) in childhood ALL compared with adult ALL.
  • The adverse effect of IKZF1 on OS and RFS was seen only in childhood ALL. No other genes had a consistent clinical effect in either childhood or adult ALL.

Conclusion

The study found recurrent somatic alterations in Korean T-ALL patients, consistent with previous studies. IKZF1 alteration was associated with an adverse effect on OS and RFS in childhood ALL. Six patients had variants in six genes associated with PID. Of the 81 genes associated with 23 predisposition syndromes, only one predisposition germline mutation (TP53) was identified. Taken together, the results indicate a low probability of germline mutation predisposition to ALL in Korean patients. However, the study was limited by the number of patients with early T-cell precursor ALL, and further studies should explore this patient group.

  1. Shin S-Y, Lee H, Lee S-T, et al. Recurrent somatic mutations and low germline predisposition mutations in Korean ALL patients. Sci Rep. 2021;11(1):8893. DOI: 1038/s41598-021-88449-4

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox